Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Zoetis Inc ha un obiettivo di prezzo di consenso pari a $206.36, stabilito in base alle ultime valutazioni degli analisti di 14. Le ultime 3 valutazioni degli analisti sono state rilasciate da Piper Sandler, Leerink Partners y Stifel il agosto 11, 2025, julio 17, 2025 y junio 18, 2025. Con un obiettivo di prezzo medio di $176.67 tra le Piper Sandler, Leerink Partners y Stifel, c'è un implicito 12.70% upside per Zoetis Inc da queste valutazioni degli analisti.
1calculado a partir de las calificaciones de los analistas
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
08/11/2025 | 37.15% | Piper Sandler | $210 → $215 | Maintains | Overweight | |||
07/17/2025 | -1.12% | Leerink Partners | $180 → $155 | Downgrade | Outperform → Market Perform | |||
06/18/2025 | 2.07% | Stifel | $165 → $160 | Downgrade | Buy → Hold | |||
05/12/2025 | 33.96% | Piper Sandler | $205 → $210 | Maintains | Overweight | |||
05/07/2025 | 8.45% | UBS | $189 → $170 | Maintains | Neutral | |||
04/14/2025 | 5.26% | Stifel | $180 → $165 | Maintains | Buy | |||
02/27/2025 | 30.77% | Piper Sandler | $200 → $205 | Maintains | Overweight | |||
02/14/2025 | 55.65% | Barclays | $242 → $244 | Maintains | Overweight | |||
02/14/2025 | 51.82% | Morgan Stanley | $243 → $238 | Maintains | Overweight | |||
02/10/2025 | 27.58% | Piper Sandler | $210 → $200 | Maintains | Overweight | |||
01/29/2025 | 55.01% | Morgan Stanley | $248 → $243 | Maintains | Overweight | |||
01/07/2025 | 14.83% | Stifel | $210 → $180 | Maintains | Buy | |||
12/09/2024 | 25.03% | UBS | — | → $196 | Initiates | → Neutral | ||
12/02/2024 | 37.15% | Leerink Partners | → $215 | Initiates | → Outperform | |||
10/11/2024 | 46.72% | JP Morgan | $225 → $230 | Maintains | Overweight | |||
09/18/2024 | 33.96% | Stifel | $200 → $210 | Maintains | Buy | |||
08/27/2024 | 27.58% | Stifel | $200 → $200 | Maintains | Buy | |||
08/14/2024 | 33.96% | Piper Sandler | $195 → $210 | Maintains | Overweight | |||
08/12/2024 | 43.53% | BTIG | $220 → $225 | Maintains | Buy | |||
08/07/2024 | 54.38% | Barclays | $230 → $242 | Maintains | Overweight | |||
08/05/2024 | 27.58% | Stifel | $180 → $200 | Maintains | Buy | |||
07/25/2024 | 40.34% | BTIG | → $220 | Initiates | → Buy | |||
05/08/2024 | 43.53% | HSBC | $230 → $225 | Maintains | Buy | |||
05/06/2024 | 25.03% | Goldman Sachs | $223 → $196 | Maintains | Buy | |||
04/30/2024 | 14.83% | Stifel | $195 → $180 | Maintains | Buy | |||
04/23/2024 | 46.72% | Barclays | $260 → $230 | Maintains | Overweight | |||
04/16/2024 | 24.39% | Piper Sandler | $220 → $195 | Reiterates | Overweight → Overweight | |||
04/02/2024 | 24.39% | Stifel | $215 → $195 | Maintains | Buy | |||
02/20/2024 | 40.34% | Piper Sandler | $215 → $220 | Maintains | Overweight | |||
02/14/2024 | 65.86% | Barclays | $255 → $260 | Maintains | Overweight | |||
01/17/2024 | 44.17% | Goldman Sachs | $190 → $226 | Maintains | Buy | |||
12/19/2023 | 46.72% | Jefferies | → $230 | Assumes | → Buy | |||
11/06/2023 | 37.15% | Piper Sandler | $210 → $215 | Maintains | Overweight | |||
10/30/2023 | 24.39% | Stifel | $205 → $195 | Maintains | Buy | |||
09/12/2023 | 30.77% | Stifel | → $205 | Reiterates | Buy → Buy | |||
09/06/2023 | 46.72% | HSBC | → $230 | Initiates | → Buy | |||
08/28/2023 | 30.77% | Stifel | $195 → $205 | Maintains | Buy | |||
08/14/2023 | 40.34% | Piper Sandler | $210 → $220 | Maintains | Overweight | |||
08/10/2023 | 35.88% | Goldman Sachs | $204 → $213 | Maintains | Buy | |||
06/14/2023 | 43.53% | Atlantic Equities | → $225 | Reiterates | Overweight → Overweight | |||
05/26/2023 | 43.53% | Atlantic Equities | → $225 | Reiterates | Overweight → Overweight | |||
05/08/2023 | 33.96% | Piper Sandler | $220 → $210 | Maintains | Overweight | |||
02/21/2023 | 65.86% | Barclays | $250 → $260 | Maintains | Overweight | |||
11/15/2022 | 58.2% | Morgan Stanley | $264 → $248 | Maintains | Overweight | |||
11/04/2022 | 14.83% | B of A Securities | $225 → $180 | Maintains | Buy | |||
11/04/2022 | 14.83% | Goldman Sachs | $207 → $180 | Maintains | Buy | |||
10/17/2022 | 43.53% | JP Morgan | $250 → $225 | Maintains | Overweight |
El último precio objetivo de Zoetis (NYSE:ZTS) fue comunicado por Piper Sandler el agosto 11, 2025. La firma de analistas fijó un precio objetivo para $215.00 que espera ZTS a rise dentro de 12 meses (un posible 37.15% upside). 17 firmas de analistas han reportado calificaciones en el último año.
La última calificación de analistas para Zoetis (NYSE:ZTS) fue proporcionada por Piper Sandler, y Zoetis mantuvo su overweight calificación.
No hay última actualización para Zoetis
La última revisión a la baja de Zoetis Inc se produjo en julio 17, 2025, cuando Leerink Partners cambió su precio objetivo de $180 a $155 para Zoetis Inc.
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Zoetis, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Zoetis se registró el agosto 11, 2025, por lo que la próxima calificación estará disponible en torno al agosto 11, 2026.
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Zoetis (ZTS) fue un mantuvo con un precio objetivo de $210.00 a $215.00. El precio actual al que cotiza Zoetis (ZTS) es de $156.76, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.